Asian Stocks Mixed, Caution Reigns Over Omicron

Asian Stocks Mixed, Caution Reigns Over Omicron By Investing.com


© Reuters.

By Gina Lee

Investing.com – Asia Pacific stocks were mixed on Monday morning, as uncertainties about the omicron COVID-19 variant continue and investors await U.S. inflation data later in the week.

Japan’s fell 0.67% by 9:19 PM ET (2:19 AM GMT) and South Korea’s edged up 0.14%.

In Australia, the was down 0.34%, with the handing down its policy decision on Tuesday.

Hong Kong’s fell 0.96%.

China’s was up 0.40% and the edged up 0.13%.

The Nasdaq Golden Dragon China Index fell to its lowest level since 2008, as the of Didi Global Inc.’s (NYSE:) potential delisting from the New York Stock Exchange, announced last week, continue to be felt. The index’s decline prompted the China Securities Regulatory Commission on Sunday to play down delisting fears on Sunday.

Chinese trade data, including , , and the , will be released on Wednesday. Inflation data, including the and , will follow a day later.

Investors continue to digest Friday’s mixed U.S. jobs report, including . More U.S. data, including the , is due later in the week, which could increase the pressure on the U.S. Federal Reserve to quicken asset tapering. Minneapolis Fed President Neel Kashkari is due to speak on Thursday.

U.S. Treasury yields climbed, trimming Friday’s fall that sent the benchmark 10-year yield closer to 1.30%.

“This week’s November CPI data could trigger markets to price‑in a more aggressive tightening cycle,” Commonwealth Bank of Australia strategist Kim Mundy said in a note.

“Omicron‑related uncertainty will linger while market participants wait to learn about the severity, infectiousness, and resistance of the strain.”

European Central Bank President Christine Lagarde will speak at a conference on Wednesday, and the Eurozone GDP will be released the day before.

On the COVID-19 front, South Africa reported that omicron is not leading to higher hospitalization rates, even as concerns over the variant continue. U.S. National Institute of Allergy and Infectious Diseases director Anthony Fauci said there did not seem to be “a great degree of severity to omicron,” but added that it is too early to be certain.

Moderna Inc. (NASDAQ:) President Stephen Hoge said there is a “real risk” that existing vaccines will be less effective against omicron.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Source link